Cardiovascular Outcomes with Empagliflozin – News for Type 2 Diabetes Therapy

Open Access

1 January 2016

journal article
Published by Touch Medical Media, Ltd. in touchREVIEWS in Endocrinology

Vol. 12 (1), 31-32
https://doi.org/10.17925/EE.2016.12.01.31

Abstract

Cardiovascular safety has to be proven for antidiabetic therapy for type 2 diabetes according to the guidance from regulatory bodies. Recently, the results of the respective study for the sodium-glucose transporter-2 (SGLT-2) inhibitor empagliflozin were published. Unlike similar studies for other antidiabetic agents that proved cardiovascular safety by non-inferiority compared with standard treatment with regard to a combined cardiovascular primary endpoint, empagliflozin showed superiority with a significantly lower incidence of cardiovascular events.

Keywords

SGLT-2 INHIBITORS
TYPE 2 DIABETES
CARDIOVASCULAR OUTCOMES
EMPAGLIFLOZIN

This publication has 7 references indexed in Scilit:

Erratum. Classification and diagnosis of diabetes. Sec. 2. In Standards of Medical Care in Diabetes – 2016 . Diabetes Care 2016;39(Suppl. 1):S13–S22
Diabetes Care, 2016
Cardiovascular Risk and Sodium–Glucose Cotransporter 2 Inhibition in Type 2 Diabetes
The New England Journal of Medicine, 2015
Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes
The New England Journal of Medicine, 2015
The Role of Sodium-Glucose Co-Transporter 2 Inhibitors in the Treatment of Type 2 Diabetes
Clinical Therapeutics, 2015
Management of Hyperglycemia in Type 2 Diabetes, 2015: A Patient-Centered Approach: Update to a Position Statement of the American Diabetes Association and the European Association for the Study of Diabetes
Diabetes Care, 2014
Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.
1998
Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). UK Prospective Diabetes Study (UKPDS) Group.
1998